✦ LIBER ✦

Reductions in Human Papillomavirus-Disease Resource Use and Costs with Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccination: The FUTURE Study Economic Evaluation

✍ Scribed by Ralph P. Insinga; Erik J. Dasbach; Shannon E. Allen; George W. Carides; Evan R. Myers

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The epidemiological and economic impact

✍ EJ Dasbach; RP Insinga; EH Elbasha 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 159 KB

Safety, immunogenicity, and efficacy of

✍ Nubia Muñoz; Ricardo Manalastas Jr; Punee Pitisuttithum; Damrong Tresukosol; Jos 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 171 KB

Response to Letter to the Editor by Tsu

✍ Joseph Monsonego 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 122 KB

PS10 Late breaking Prophylactic use of q

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 63 KB